5-[7-[2-(azetidin-1-yl)ethylamino]-1-fluoro-3-hydroxy-2-naphthyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one

ID: ALA5084112

PubChem CID: 155103480

Max Phase: Preclinical

Molecular Formula: C17H19FN4O4S

Molecular Weight: 394.43

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  O=C1CN(c2c(O)cc3ccc(NCCN4CCC4)cc3c2F)S(=O)(=O)N1

Standard InChI:  InChI=1S/C17H19FN4O4S/c18-16-13-9-12(19-4-7-21-5-1-6-21)3-2-11(13)8-14(23)17(16)22-10-15(24)20-27(22,25)26/h2-3,8-9,19,23H,1,4-7,10H2,(H,20,24)

Standard InChI Key:  ZFWRAIFJAPDBFC-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 30  0  0  0  0  0  0  0  0999 V2000
   25.2118   -9.5581    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   26.0117   -9.7747    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   25.7993   -8.9736    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   22.3687  -11.0288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.3675  -11.8562    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.0824  -12.2690    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.0806  -10.6161    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.7959  -11.0251    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.7967  -11.8520    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.5120  -12.2629    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.2270  -11.8482    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.2222  -11.0183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.5063  -10.6110    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.9333  -10.5990    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   26.6889  -10.9299    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.2372  -10.3135    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.8203   -9.6015    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.0581  -10.3947    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.5020   -9.7860    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   25.9431  -12.2579    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   21.6542  -10.6165    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.9399  -11.0292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.2252  -10.6168    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.5109  -11.0295    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.7157  -10.8129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5023  -11.6098    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.2992  -11.8232    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  2  0
  5  6  1  0
  6  9  2  0
  8  7  2  0
  7  4  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13  8  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17  2  1  0
  2 14  1  0
 12 14  1  0
 16 18  2  0
 13 19  1  0
 11 20  1  0
  4 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5084112

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 394.43

Molecular Weight (Monoisotopic): 394.1111

AlogP: 0.98

#Rotatable Bonds: 5

Polar Surface Area: 101.98

Molecular Species: ACID

HBA: 6

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 3.77

CX Basic pKa: 8.03

CX LogP: -1.33

CX LogD: -1.31

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.70

Np Likeness Score: -1.05

References

1. Abdel-Magid AF..  (2022)  The Inhibitors of Protein Tyrosine Phosphatase Nonreceptor Type 2 (PTPN2) as Potential Enhancers of Cancer Immunotherapy and Type 1 (PTPN1) as Treatment of Metabolic Diseases.,  13  (1.0): [PMID:35059117] [10.1021/acsmedchemlett.1c00678]

Source

Source(1):

• Scientific Literature